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Objective: To report the efﬁcacy of a 3-month treatment program consisting of neuromuscular exercise,
education, diet, insoles and pain medication (MEDIC-treatment) compared to usual care (two leaﬂets
with information and treatment advice) in reducing pain-related measures and sensitization in patients
with knee osteoarthritis (OA) not eligible for total knee replacement (TKR).
Method: A pre-deﬁned ancillary analysis of the results at 3 months of a randomized controlled trial (RCT)
of 100 patients randomized to MEDIC-treatment or usual care. Trial registration: ClinicalTrials.gov
(NCT01535001). Outcomes were sensitization assessed at the knee, the lower leg and forearm using a
handheld algometer, peak pain intensity in the previous 24 h, pain intensity after 30 min of walking, pain
location and pattern, spreading of pain (a region-divided body chart) and the usage of pain medication.
Results: The MEDIC group had larger improvements from baseline to 3 months in peak pain intensity
(P ¼ 0.02) and pain after 30 min of walking (P < 0.001) and in the number of body sites with pain
(P ¼ 0.04). There was no difference in the change in sensitization from baseline to 3 months between
groups (P ¼ 0.87), but sensitization decreased in both groups (P < 0.001).
Conclusion: A non-surgical treatment program is more efﬁcacious in reducing pain-related measures
than usual care, while both are equally efﬁcacious in reducing sensitization, indicating that mechanisms
other than pain sensitization contribute to the perceived pain. The patients did not have severe symp-
tomatic knee OA and hence pain sensitization may not yet have developed into a clinically relevant
parameter or subgroups with less sensitization may exist.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Pain associated with knee osteoarthritis (OA) is recognized as a
complex phenomenon encompassing several mechanisms1,.T. Skou, Orthopaedic Surgery
h and Innovation Centre, 15
-23-70-86-40.
alth.sdu.dk (E.M. Roos), ohs@
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sen), sten.rasmussen@rn.dk
ternational. Published by Elsevier Lindicating that its assessment2 and treatment3 should be multi-
modal to target all co-responsible mechanisms. Pain intensity, us-
age of pain medication, pain pattern and spreading of pain are
important pain-related measures2,4,5. Another pain mechanism
known to be important in patients with advanced knee OA is
sensitization4,6,7, deﬁned as increased responsiveness of nocicep-
tive neurons to their normal input, and/or recruitment of a
response to normally subthreshold inputs8.
Quantitative sensory testing (QST) can be used to assess sensi-
tization in patients with knee OA using a mechanism-based
approach3. By assessing the somatosensory response evoked by
applying controlled noxious or innocuous stimuli (e.g., using atd. All rights reserved.
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patient9. Compared to healthy controls, pressure pain sensitivity
found locally at the affected knee (and adjacent body parts) in
patients with chronic pain can be associatedwith peripheral and/or
central sensitization, while pressure pain sensitivity distantly from
the knee may reﬂect generalized central sensitization (spreading
sensitization) only4,9. Both peripheral and spreading sensitization
have previously been demonstrated in patients with knee OA
compared to pain-free controls6,10e14, although they have mostly
been investigated in more advanced knee OA. Evidence regarding
sensitization in patients with less advanced knee OA is scarce.
While the evidence concerning the efﬁcacy of non-surgical
treatment on knee OA pain is strong15,16, less attention has been
paid to its efﬁcacy on sensitization processes17,18. Two previous
studies have assessed the effects of exercise on sensitization in knee
OA, but with conﬂicting results13,19. Henriksen et al.19 demonstrated
that 12 weeks of supervised exercise reduced pressure pain sensi-
tivity compared to a no-attention control group, while Kosek et al.13
found that exercise (average duration of 12 weeks) had no effect on
pressure pain sensitivity. Furthermore, no studies have investigated
the combined efﬁcacy of the recommended treatments in reducing
both pain and sensitization even though this could improve
outcome18.
A previously published20 randomized controlled trial (RCT)
showed that a 3-month treatment program of neuromuscular ex-
ercise, education, diet, insoles and pain medication (the MEDIC-
treatment) resulted in greater long-term improvements in pain,
function and quality of life (QOL) outcomes compared to informa-
tion and treatment advice (usual care) in patients with knee OA not
eligible for total knee replacement (TKR). The aim of this pre-
speciﬁed ancillary analysis was to investigate the efﬁcacy of the
MEDIC-treatment to improve different pain-related measures (pain
intensity, pain location and pattern, spreading of pain and usage of
pain medication) and sensitization after 3 months compared to
usual care.
We hypothesized that the MEDIC-treatment would result in
greater improvements in the pain-related measures and sensiti-
zation than usual care at 3-month follow-up.Method
Study design
This was an ancillary analysis of the 3-month results from a two-
arm parallel group assessor-blinded RCT (1:1 treatment allocation)
conforming to the CONSORT statement for reporting RCTs21. The
current analyses were pre-deﬁned in the statistical analysis plan
(made available before unblinding the data)22.
All details of the recruitment process, full eligibility criteria, the
process of randomization, allocation concealment and detailed
description of the intervention have been published previously23.Patients
One hundred patients with radiographic and symptomatic knee
OA found not eligible for TKR by an orthopedic surgeon, but
experiencing more than mild limitations, were enrolled. Patients
were recruited from two specialized, public outpatient clinics at
Aalborg University Hospital (Frederikshavn and Farsoe, 50 patients
from each clinic) between 3 April 2012 and 12 July 2013. Major
exclusion criteria were scores above 75 in the self-report ques-
tionnaire Knee Injury and Osteoarthritis Outcome Score (KOOS)4,
deﬁned as the average score for the subscale scores for pain,
symptoms, activities of daily living (ADL) and QOL, previousipsilateral knee replacement and mean knee pain in the previous
week greater than 60 mm on a 0e100 mm visual analogue scale
(VAS).
All patients gave informed consent before being enrolled, and
the study was conducted in accordance with the Helsinki declara-
tion and approved by the local Ethics Committee of The North
Denmark Region (N-20110085). Furthermore, this ancillary study
was registered at ClinicalTrials.gov (NCT01535001).
Intervention
The MEDIC-treatment
The 3-month MEDIC-treatment consisted of prescribing edu-
cation, exercise and insoles to everyone in the MEDIC group,
while weight loss and/or pain medication were prescribed if
indicated. The treatment was given at Aalborg University Hospital,
Denmark, by physiotherapists and dieticians trained in providing
the treatment to ensure standardization of the treatment
program.
Education. Two 60-min sessions of education focusing on disease
characteristics, OA pain and how to control and monitor it during
exercise, treatment and help to self-help by actively engaging the
patients.
Exercise. The MEDIC group participated in The NEuroMuscular
EXercise training program (NEMEX), previously found feasible in
patients with moderate to severe knee OA24, twice weekly with
each session lasting 60 min. The program is based on neuro-
muscular and biomechanical principles with different levels of
difﬁculty for each exercise24. To improve long-term adherence,
the exercise program was followed by a transition period of 8
weeks to gradually accustom the patients to continue exercising
at home.
Dietary advice. If patients had a body mass index (BMI) 25 at
baseline, they underwent a dietary weight loss program based on
principles from motivational interviewing, with instructions and
advice related to the readiness of the individual patient to change
dietary habits and take action25. It consisted of four 60-min ses-
sions, with the aim of reducing body weight by at least 5%26.
Insoles. A set of individually ﬁtted full-length Formthotics System
insoles with medial arch support (Foot Science International,
Christchurch, New Zealand) was given to the patients. Patients with
a knee knee-lateral-to-foot position (the knee moves over or lateral
to the 5th toe in three or more of ﬁve trials of the valid and reliable
single limbmini squat test27) had a 4 lateral wedged added to their
insole.
Pain medication. If found relevant, paracetamol 1 g four times daily,
ibuprofen 400 mg three times daily, and pantoprazol 20 mg daily
were prescribed. The prescription was reassessed every 3 weeks to
supervise the use and indications of the medication. If the contin-
uation of the pain medicine during the 3-week period was ques-
tioned by the patient (e.g., due to pain relief), the patients were
instructed to contact the project physiotherapist.
Usual care
The usual care group was given two standardized information
leaﬂets. These included information on knee OA with regard to
etiology, symptoms, common functional limitations, recommended
treatments and general advice on how to address the symptoms
yourself and information on where in The North Denmark Region
they could seek advice regarding treatment and general
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designed to reﬂect current treatment of patients with knee OA in
clinical practice, which has been demonstrated to be suboptimal
compared to clinical guidelines28,29.
Outcomes
Both the baseline and 3-month follow-up were carried out at
the Department of Occupational Therapy and Physiotherapy, Aal-
borg University Hospital, Denmark, by the same outcome assessor.
The assessor was unafﬁliated with the treatment sites, blinded to
treatment allocation, and speciﬁcally trained in all aspects of the
assessments.
Assessment of pain
Peak pain intensity in the most affected knee during the pre-
vious 24 h was assessed on a 100 mm VAS with terminal de-
scriptors of ‘no pain’ and ‘worst pain possible’. We chose peak pain
intensity since it has been frequently applied in studies on sensi-
tization in knee OA-related pain6,7,30. The VAS is a measure of pain
widely used in patients with knee OA that is valid, reliable and
responsive31.
Pain intensity during function. Knee pain intensity after 30 min of
walking was assessed on a 100-mm VAS with terminal descriptors
of ‘no pain’ and ‘worst pain possible’. Pain intensity after 30 min of
walking was chosen, since it can serve as an indirect measure of
how knee pain affects function.
Knee pain location and pattern. Knee pain location and pattern in
the most affected knee were assessed using the reliable
interviewer-administered questionnaire Knee Pain Map previously
applied in patients with knee OA5. The Knee Pain Map identiﬁes
painful areas of the knee and characterizes the pain as localized,
regional or diffuse5. Since diffuse pain is indicative of a more pro-
gressed sensitization4, the pain location and pattern were dichot-
omized (diffuse pain in the most affected knee yes/no).
Spreading of pain. The patients were asked to shade body sites with
pain in the previous 24 h on a region-divided body chart (26 sites in
total). The number of pain sites was applied to classify the
spreading of pain as previously suggested in a large-scale study on
multisite pain32.
Usage of pain medication. This was deﬁned as any pain medication
taken on a regular basis during the last week at baseline and at the
3-month follow-up. The results were dichotomized (pain medica-
tion yes/no) due to non-uniformity of the distribution of pain
medication intake.
Assessment of sensitization
Pressure pain thresholds (PPTs) were measured bilaterally us-
ing a handheld algometer with a 1 cm2 probe (Algometer Type II,
Somedic AB, Hoerby, Sweden). The pressure was applied perpen-
dicular to the skin at a constant rate of 30 kPa/s until the patient
felt the pressure change to pain and pressed a button deﬁning the
PPT. One or two test assessments were performed at the dorsal
aspect of the hand to ensure that the patient understood the
procedure. The test procedure has previously been assessed in a
testeretest reliability and agreement study with 20 patients with
knee OA that demonstrated intraclass correlation coefﬁcients
(two-way random-effects model, consistency-type) and 95% limits
of agreement (95% LOA; presented as the difference between the
mean difference and the upper and lower LOA) ranging from 0.84
to 0.91 and 199.6 to 434.0 kPa33 for the different sites. The 95%LOA corresponds to the minimal detectable change (MDC) for the
assessment method.
Localized sensitization. Localized sensitization (peripheral sensiti-
zation) was assessed using PPTs from four sites at the knee, all in
proximity to the patella: (1) 3 cm medial to the midpoint of the
medial edge, (2) 2 cm proximal to the midpoint of the superior
edge, (3) 3 cm lateral to the midpoint of the lateral, and (4) at the
centre6. PPTs were obtained twice at each site, and the mean of all
four sites was used in the analyses.
Spreading sensitization. Spreading sensitization (central sensitiza-
tion) was assessed using PPTs from the tibialis anterior muscle
(lower leg: 5 cm distal to the tibial tuberosity), and the extensor
carpi radialis longus muscle (forearm: 5 cm distal to the lateral
epicondyle of the humerus)6. PPTs were obtained twice at each site,
and the means for the lower leg and for the forearm were used in
the analyses.
Statistical analysis
Sample size
The sample size was calculated based on the pre-deﬁned pri-
mary hypothesis regarding peak pain intensity. The sample size
needed to detect a 10-point difference (SD 14) between groups in
peak pain intensity was 41 patients in each group (power of 90%
and a signiﬁcance level at 0.05 (two-sided)). To account for any
TKRs performed during follow-up and for missing data, the dropout
rate was set to 20%, and a total of 100 patients were randomized.
Due to the ancillary nature of this pre-speciﬁed analysis, the sample
size was deemed adequate for providing additional characteriza-
tion of the effects of the MEDIC-treatment.
Ancillary analyses
Since this was an ancillary analysis, only patients (not under-
going a TKR) with available data from both the baseline and 3-
month follow-up were included in the analyses. No adjustments
for multiplicity were done as endorsed by The European Agency for
the Evaluation of Medicinal Products when ancillary analyses are
declared as supportive34.
A Student's t-test was used to evaluate change in pain intensity
and number of pain sites between and within groups. A three-way
analysis of variance (ANOVA) was used to evaluate change in PPT
from baseline to 3 months using the ﬁxed factors group (MEDIC,
usual care), site (knee, lower leg and forearm) and side (most affected,
contralateral). The analysis was conducted both unadjusted and
adjusted (baseline PPT, gender and age). Within-group changes in
PPTs due to the treatment were further assessed using repeated
measures ANOVAwith time (baseline, 3 months), site (knee, lower leg
and forearm) and side (most affected, contralateral) as the within-
subject factor for both the MEDIC group and the usual care group.
The assumption of homogeneity of variance was tested using Lev-
ene's test (P > 0.05), and the assumption of normal distributionwas
tested by visual inspection of QeQ plots. If ﬁndings were non-
signiﬁcant, a sensitivity-analysis was performed that included
only those participating in at least 75% of the exercise sessions.
TukeyeKramer was used as a post hoc test if ANOVA factors or
interactions were signiﬁcant.
The relative risks for usage of pain medication and diffuse pain
were estimated and compared between groups using a Poisson
regression model with a robust error variance for the conﬁdence
intervals.
The signiﬁcance level was set at P < 0.05, and all analyses were
performed in either IBM SPSS Statistics (Version 22, IBM
Table II
Pain location and pattern at baseline in the most affected knee
Pain location and pattern, n (%) MEDIC (n ¼ 49) Usual care (¼47)
Diffuse* 34 (69) 26 (55)
Regional 13 (27) 21 (45)
Medial region 9 (18) 12 (26)
Patella region 2 (4) 2 (4)
Lateral region 1 (2) 3 (6)
Back of knee, regional 0 (0) 0 (0)
Localized 13 (27) 21 (45)
Superior medial 1 (2) 0 (0)
Medial joint line 10 (20) 13 (28)
Inferior medial 4 (8) 6 (13)
Patella, local 2 (4) 2 (4)
Superior lateral 0 (0) 1 (2)
Lateral joint line 1 (2) 3 (6)
Inferior lateral 1 (2) 3 (6)
Back of knee, local 0 (0) 0 (0)
* Of these, 20 in theMEDIC group and 13 in the usual care groupwere classiﬁed as
diffuse pain due to either >3 areas of localized pain, >2 regions of pain, and/or >1
location and 1 non-overlapping region32,33.
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Station, TX, USA).
Results
In all, 654 patients seen in secondary care by an orthopedic
surgeon were assessed for eligibility, 553 were excluded, and one
was not willing to undergo randomization. The primary reasons
for exclusion were being eligible for a TKR (n ¼ 192), no radio-
graphic OA (KellgreneLawrence score <1; n ¼ 87), and inability to
comply with the study protocol (n ¼ 159). One hundred patients
were randomized, with 43/50 (86%; one patient underwent TKR
during the 3 months) in the MEDIC group and 46/50 (92%) in the
usual care group completing both baseline and 3-month follow-
up. For further information on the study ﬂow, please refer to20.
Patient characteristics of the groups at baseline are presented in
Table I and pain location and pattern at baseline are presented in
Table II.
Between-group analyses
Peak pain intensity
There was a statistically signiﬁcant difference in change (95%
conﬁdence interval (CI)) from baseline to 3 months of 15.4
(2.6e28.2) in peak pain intensity (P ¼ 0.019), favoring the MEDIC
group.
Pain intensity during function
Therewas a statistically signiﬁcant difference in change (95% CI)
from baseline to 3 months of 32.6 (18.1e45.0) in pain intensity after
30 min of walking (P < 0.001) favoring the MEDIC group.
Knee pain location and pattern
There was no signiﬁcant difference between groups in the
number of patients with diffuse pain at 3 months compared to
baseline.
Spreading of pain
Therewas a statistically signiﬁcant difference in change (95% CI)
from baseline to 3 months of 0.86 (0.03e1.70) in number of sites
with pain (P ¼ 0.042), favoring the MEDIC group.Table I
Patient characteristics
Patient characteristics
Women, n (%)
Age (years), mean (SD)
Body mass index, mean (SD)
Study knee, n right (%)
Bilateral knee pain, n (%)
Duration of knee symptoms, n (%)
0e6 months
6e12 months
1e2 years
2e5 years
5e10 years
More than 10 years
Radiographic knee OA severity (KellgreneLawrence), n (%)
Grade 1
Grade 2
Grade 3
Grade 4
Peak pain intensity in the previous 24 h (0e100), mean (SD)
Pain intensity after 30 min walking (0e100), mean (SD)
Have used pain medication in the last week, n (%)
Body sites with pain, mean (SD)Fig.1 illustrates the difference in body sites with pain at baseline
and after 3 months in the MEDIC group and the usual care group.Usage of pain medication
There was no signiﬁcant difference between groups in the usage
of pain medication at 3 months compared to baseline.Localized and spreading sensitization
No statistical difference in change in PPTs from baseline to 3
months was found between groups in the crude analysis
[F(1, 468) ¼ 0.028, P ¼ 0.868] or when adjusting for baseline PPT,
age and gender [F(1, 465) ¼ 0.015, P ¼ 0.902; Fig. 2]. Including only
those participating in at least 75% of the exercise sessions in
the MEDIC group still demonstrated no statistical difference in
change in PPTs from baseline to 3 months between groups
[F(1, 366) ¼ 0.585, P ¼ 0.445].Within-group analyses
Within-group results are presented in Tables IIIeV.MEDIC Usual care
26 (52) 25 (50)
64.8 (8.7) 67.1 (9.1)
30.6 (5.6) 29.4 (5.2)
18 (36) 27 (54)
18 (36) 21 (42)
4 (8) 2 (4)
9 (18) 6 (12)
10 (20) 5 (10)
11 (22) 13 (26)
4 (8) 8 (16)
12 (24) 16 (32)
7 (14) 11 (22)
13 (26) 15 (30)
13 (26) 10 (20)
17 (34) 14 (28)
60 (23) 56 (25)
62 (26) 47 (24)
32 (64) 30 (60)
3.2 (2.9) 2.8 (2.1)
Fig. 1. Pain sites. Sites of the body where at least 10% of the patients in the MEDIC group (A) and in the usual care group (B) reported pain during the previous 24 h. A black shade
indicates that at least 10% reported pain at both baseline and at the 3-month follow-up, while a gray shade indicates that at least 10% reported pain at baseline, but not at the 3-
month follow-up. The right side of the body in the ﬁgures has been set as the side mostly affected by knee OA.
Fig. 2. PPTs on the most affected side. Mean PPTs measured in kPa using a handheld
algometer on the knee, lower leg and forearm. No between-group differences were
found, while signiﬁcantly higher PPTs (*; P < 0.05) were found for all sites on both the
most affected and contralateral side after 3 months in both the MEDIC group and the
usual care group. Error bars indicate 95% CI.
Table IV
Diffuse knee pain in the most affected knee
Outcome MEDIC group (95% CI) Usual care group (95% CI)
Proportion with diffuse knee pain* (nMEDIC, nusual care)
Baseline (41, 40) 0.78 (0.63e0.88) 0.53 (0.37e0.68)
3 months (41, 40) 0.45 (0.31e0.61) 0.40 (0.26e0.56)
Risk ratio for having diffuse pain at 3 months vs baseline
Crude estimate 0.47 (0.32e0.69) 0.76 (0.52e1.12)
Risk ratio for having diffuse pain at 3 months in the usual care group vs MEDIC
group
Crude estimate 0.91 (0.52e1.60) e
* The deﬁnition of diffuse knee pain is from the Knee Pain Map32,33.
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This study showed that a 3-month non-surgical treatment
program was associated with greater improvements in outcome
with regard to pain intensity and spreading of bodily pain, but not
sensitization, knee pain pattern and usage of pain medication after
3 months compared to information and treatment advice inTable III
Within-group analyses
Outcome MEDIC group
F statistics (df) or Mean improvements (95% CI)
Peak pain intensity 27.9 (18.4e37.5)
Pain intensity after walking 34.8 (25.0e44.6)
Body sites with pain 1.19 (0.49e1.89)
Pressure pain thresholds* 14.334 (1, 40)
* There was a signiﬁcant interaction between time and site [F(2, 80) ¼ 5.783, P ¼ 0.00patients with knee OA not eligible for TKR. These ﬁndings conﬁrm
that pain has a multitude of facets, and that treatment results may
differ depending onwhat pain-relatedmeasures are evaluated. This
is the ﬁrst study evaluating multiple pain-related measures,
including sensitization, in a randomized setting in patients with
knee OA.Comparison to previous studies on pain
We demonstrated large between-group differences with regard
to change in pain intensity from baseline to 3 months, conﬁrming
previous RCTs on the efﬁcacy of a non-surgical treatment program
in reducing pain in patients with knee OA35,36. Furthermore, our
study extends these ﬁndings by adhering to the recommendationP value Usual care group P value
F statistics (df) or Mean improvements (95% CI)
<0.001 13.4 (4.3e22.5) 0.005
<0.001 2.7 (6.9e12.3) 0.574
0.001 0.33 (0.16e0.81) 0.179
0.001 10.908 (1, 38) 0.002
5; Fig. 2] in the MEDIC group. No other interactions were found.
Table V
Usage of pain medication
Outcome MEDIC group (95% CI) Usual care group (95% CI)
Proportion of users of pain medication* (nMEDIC, nusual care)
Baseline (42, 44) 0.69 (0.53e0.81) 0.55 (0.40e0.69)
3 months (42, 44) 0.45 (0.31e0.61) 0.66 (0.51e0.78)
Risk ratio for taking pain medication at 3 months vs baseline
Crude estimate 0.66 (0.47e0.92) 1.21 (0.92e1.58)
Risk ratio for taking pain medication at 3 months in the usual care group vs
MEDIC group
Crude estimate 1.46 (0.98e2.17) e
* User of pain medication was deﬁned as patients taking pain medication of any
kind on a regular basis during the last week.
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alone should be addressed2, thus giving a broad perspective on the
effects of a non-surgical treatment program in patients with knee
OA. In addition to improvements in pain intensity, we demon-
strated that the MEDIC group had a larger reduction in the number
of body sites with pain following the treatment as compared with
the usual care group and a within-group reduction in the propor-
tion using pain medication. This could be related to systemic anti-
inﬂammatory effects from exercise that have previously been
suggested to be the reason for the protective effects of exercise on
cardiovascular disease and type 2 diabetes37 and improvements in
well-being and other psychosocial components that have been
demonstrated to result from exercise38. Furthermore, education,
i.e., teaching the patient about the etiology of the pain and how to
deal with it, is known to be effective in the treatment of chronic
musculoskeletal pain39, thereby offering an additional explanation
for the ﬁndings. Either way, the reduction of total body sites with
pain as a result of non-surgical treatment of the knee is promising
because musculoskeletal pain has been suggested to spread over
time4, and because having pain elsewhere is signiﬁcantly associ-
ated with persistent pain after joint replacement40e42. A recent
study applying the same region-divided body chart that we used
demonstrated that patients with chronic knee pain after revision
TKR (all undergoing their primary TKR due to knee OA) had a mean
of six body sites with pain and a mean pain duration of approx. 14
years43, while the patients in our study had a mean of three body
sites with pain and only 28% of the patients had knee pain for more
than 10 years. Even though a direct linkage between the spreading
of pain and the duration cannot be established based on cross-
sectional data, these results offers some support to the proposi-
tion that pain will become widespread over time if not treated
properly4 This notion is further supported by a prospective study by
Andersen et al.44 showing that chronic pain in the knees increase
the risk of developing chronic pain elsewhere over time. This
highlights the potential of multimodal treatment for pain relief in
patients with knee OA.
Comparison to previous studies on sensitization
While the previous studies investigating the efﬁcacy of exercise
on sensitization in knee OA, a RCT19 and a controlled before-and-
after study13, both included a passive control group, we advised
our control group to initiate non-surgical treatment on their own,
thereby resembling contemporary treatment in patients with knee
OA found not eligible for TKR. In the MEDIC group of our study, the
proportionwith diffuse knee painwas reduced following treatment
indicating an improvement in sensitization. In both groups, im-
provements were seen in measures reﬂecting localized sensitiza-
tion (peripheral sensitization: PPTs from the knee) and spreading
sensitization (central sensitization: PPTs from the lower leg and
forearm), but we found no signiﬁcant difference in sensitizationbetween groups. Furthermore, the improvements within groups
were smaller than theMDC for handheld algometry33, which is why
it cannot be ruled out that the lack of difference between groups
was actually caused by measurement uncertainty. Differences in
measurement uncertainty could also help explain the conﬂicting
results in the two previous studies, since the study by Kosek et al.13
also applied a handheld algometer in the assessment of sensitiza-
tion, while Henriksen et al.19 applied a computer-controlled cuff
algometer that is less affected by measurement variability45.
However, it is important to recognize that the differences in PPT
found by Henriksen et al.19 were small and of questionable clinical
relevance. All together, this indicates that sensitization may not be
an ideal outcome measures in trials in the general population of
patients with knee OA.
Sensitization in knee OA e only relevant for a subgroup of patients?
The so far conﬂicting results on the effects of non-surgical
treatment on sensitization compared to the vast body of evidence
supporting the effects of the same treatments on pain16 could
potentially be explained by the presence of subgroups of OA pa-
tients with more sensitization and OA patients with less or no
sensitization46,47. Despite similar clinical pain intensities, a sub-
group of patients with knee OA who had high local knee pain
sensitivity to pressure had higher pain sensitivity to pressure at the
lower leg and the forearm than those with low local knee pain
sensitivity7. This highlights that subgroups with more pronounced
sensitization exist within a group of patients with knee OA with
similar severities of symptomatic knee OA. Subgroups may how-
ever exist even among those considered being healthy, since the
variability in PPTs is large in a healthy population48. PPTs from the
knee (approx. 600 kPa), lower leg (approx. 500 kPa) and forearm
(approx. 350 kPa) in pain-free subjects of comparable age and
gender distribution6 are similar to those demonstrated at baseline
in our study. In the same study, those severely affected by sensiti-
zation had amean knee pain intensity of 80 out of 1006, indicating a
more progressed knee OA than the study population in our study
(mean pain of 58 out of 100). Since knee OA pain intensity is related
to the severity of the sensitization6,7,12,30,49, this suggests that the
pain sensitization may not yet have developed into a clinical rele-
vant parameter in our study population, potentially explaining the
non-signiﬁcant differences between groups. Targeting non-surgical
treatment of sensitization towards those actually affected by the
problem has the potential to desensitize the central nervous system
by affecting mechanisms involved in the sensitization18.
Limitations
The nociceptive input in knee OA could originate from several
sources, including periarticular tissues, inﬂammation, elevated
intraosseous pressure in the subchondral bone, and elevation of
periosteum by osteophyte growth50. Since the PPTs of our study
were not speciﬁc to all these structures, it is unclear whether PPTs
actually reﬂect the true pain and sensitization of the knee OA joint.
However, the PPT measurement sites have been applied in several
previous studies successfully differentiating between different
levels of sensitization in patients with knee pain6,7,12,43. Due to the
multimodal setup of the treatment program, it is unknown
whether all components of the MEDIC-treatment are required for
the improvements in pain outcomes, and at the same time, the
multimodal setup makes it impossible to identify the efﬁcacy of an
individual treatment modality alone. However, since the treatment
program adheres to current guidelines on the treatment of knee
OA15,16 and is embedded in secondary health care, the strengths of
the design are considered to outweigh the limitations.
S.T. Skou et al. / Osteoarthritis and Cartilage 24 (2016) 108e116114Conclusions
A combined treatment with neuromuscular exercise, patient
education, diet, insoles and pain medication resulted in greater
improvements in pain intensity and spreading of pain outcomes
than usual care (information and advice) in patients with knee OA
not eligible for TKR. For this patient population no differences in
effect were seen on sensitization parameters, knee pain pattern and
usage of painmedication after 3months of the combined treatment
compared to usual care. This suggests that sensitization, as
measured in our study, is less useful as an outcome measure in
trials of the general knee OA population.
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